MARKET

OBSV

OBSV

Obseva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.41
+0.03
+0.41%
Closed 16:00 10/21 EDT
OPEN
7.62
PREV CLOSE
7.38
HIGH
7.78
LOW
7.40
VOLUME
31.57K
TURNOVER
--
52 WEEK HIGH
17.87
52 WEEK LOW
7.14
MARKET CAP
275.14M
P/E (TTM)
-3.2463
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OBSV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OBSV News

  • Do Directors Own ObsEva SA (NASDAQ:OBSV) Shares?
  • Simply Wall St..10/14 18:54
  • Key events next week - healthcare
  • Seeking Alpha - Article.10/11 11:24
  • ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
  • Benzinga.10/11 07:49
  • ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
  • GlobeNewswire.10/11 05:00

More

Industry

Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+0.40%

Hot Stocks

Name
Price
%Change

About OBSV

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).
More

Webull offers Obseva SA (OBSV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.